The perspectives of targeted therapy for classical Hodgkin's lymphoma

The survey deals with the latest results of investigations on targeted therapy for classical Hodgkin’s lymphoma (cHL). The most impressive results were achieved in the clinical trials of SGN-35 (brentuximab vedotin or adcetris) - immunotoxin on the basis of anti-CD30. Now it is planned to test SGN-35 as a component of the first-line therapy. Probably the use of that drug will make it possible to reduce the number of chemotherapy cycles and to refuse from irradiation in patients with beneficial prognostic features. Among other promising modalities of targeted therapy of cHL we can also name panobinostat and cytotoxic T-lymphocites.